JP2021514193A - Ｂｃｍａ結合抗体及びその使用 - Google Patents

Ｂｃｍａ結合抗体及びその使用 Download PDF

Info

Publication number
JP2021514193A
JP2021514193A JP2020544223A JP2020544223A JP2021514193A JP 2021514193 A JP2021514193 A JP 2021514193A JP 2020544223 A JP2020544223 A JP 2020544223A JP 2020544223 A JP2020544223 A JP 2020544223A JP 2021514193 A JP2021514193 A JP 2021514193A
Authority
JP
Japan
Prior art keywords
seq
bcma
antibody
cell
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020544223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514193A5 (https=
Inventor
アブバシアン マハン
アブバシアン マハン
チャン ヘンリー
チャン ヘンリー
ハリハラン カンダサミー
ハリハラン カンダサミー
サン ジョンフン
サン ジョンフン
ウルムセル アンドリュー
ウルムセル アンドリュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2021514193A publication Critical patent/JP2021514193A/ja
Publication of JP2021514193A5 publication Critical patent/JP2021514193A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020544223A 2018-02-21 2019-02-20 Ｂｃｍａ結合抗体及びその使用 Pending JP2021514193A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633152P 2018-02-21 2018-02-21
US62/633,152 2018-02-21
PCT/US2019/018698 WO2019164891A1 (en) 2018-02-21 2019-02-20 Bcma-binding antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2021514193A true JP2021514193A (ja) 2021-06-10
JP2021514193A5 JP2021514193A5 (https=) 2023-08-29

Family

ID=65686040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544223A Pending JP2021514193A (ja) 2018-02-21 2019-02-20 Ｂｃｍａ結合抗体及びその使用

Country Status (15)

Country Link
US (2) US11401336B2 (https=)
EP (1) EP3755718A1 (https=)
JP (1) JP2021514193A (https=)
KR (1) KR20200123155A (https=)
CN (1) CN112272675A (https=)
AR (1) AR115257A1 (https=)
AU (1) AU2019223076A1 (https=)
BR (1) BR112020017053A2 (https=)
CA (1) CA3092037A1 (https=)
EA (1) EA202091974A1 (https=)
IL (1) IL276548A (https=)
MX (1) MX2020008718A (https=)
SG (1) SG11202007495SA (https=)
TW (1) TW202000701A (https=)
WO (1) WO2019164891A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021099944A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
CN115803027A (zh) * 2020-04-30 2023-03-14 百时美施贵宝公司 治疗细胞因子相关的不良事件的方法
MX2023003041A (es) 2020-09-16 2023-05-09 Amgen Inc Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
US20250276092A1 (en) * 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies
WO2026072709A1 (en) 2024-09-25 2026-04-02 Orna Therapeutics, Inc. Chimeric antigen receptors targeting bcma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223111A1 (en) * 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5998656A (en) 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5475011A (en) 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5763477A (en) 1994-07-22 1998-06-09 Dr. Reddy's Research Foundation Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III
AU5305796A (en) 1995-03-10 1996-10-02 Hauser Chemical Research, Inc. Cephalomannine epoxide, its analogues and a method for preparing the same
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
DE122007000079I2 (de) 1996-07-24 2010-08-12 Celgene Corp Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
NZ334148A (en) 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
TR200101502T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
CN1342146A (zh) 1999-03-18 2002-03-27 塞尔基因公司 取代的1－氧代－和1,3－二氧代异吲哚啉及其在用于减少炎性细胞因子含量的药物组合物中的用途
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
NZ555886A (en) 2004-12-01 2009-12-24 Celgene Corp Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders
EP1848433A2 (en) 2005-01-25 2007-10-31 Celgene Corporation Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
UA91560C2 (ru) 2005-08-31 2010-08-10 Селджин Корпорэйшн Соединения ряда изоиндолимидов, их композиция и применение
ME02420B (me) 2006-09-26 2016-09-20 Celgene Corp 5-supstituirani derivati kinazolinona kao sredstva protiv raka
CA2734330A1 (en) * 2008-09-19 2010-03-25 Medimmune, Llc Antibodies against sonic hedgehog homolog and uses thereof
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
DK2683708T3 (da) 2011-03-11 2018-01-29 Celgene Corp Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
KR102526945B1 (ko) * 2014-04-30 2023-04-27 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
BR112017001183A2 (pt) * 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
HRP20191873T1 (hr) * 2014-12-12 2020-01-24 Bluebird Bio, Inc. Kimerni antigenski receptori
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table
TWI703159B (zh) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
US10294304B2 (en) 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen
SI3331910T1 (sl) 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
CN108473575B (zh) * 2015-11-13 2022-04-19 美国卫生和人力服务部 抗-bcma多肽和蛋白质
TWI795133B (zh) * 2016-04-01 2023-03-01 美商凱特製藥公司 Ｂｃｍａ結合分子類及彼等之用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223111A1 (en) * 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies

Also Published As

Publication number Publication date
US20220324991A1 (en) 2022-10-13
US11401336B2 (en) 2022-08-02
WO2019164891A9 (en) 2020-09-17
BR112020017053A2 (pt) 2020-12-15
MX2020008718A (es) 2020-12-07
EA202091974A1 (ru) 2020-12-08
AU2019223076A1 (en) 2020-10-08
TW202000701A (zh) 2020-01-01
WO2019164891A1 (en) 2019-08-29
AR115257A1 (es) 2020-12-16
US20200399386A1 (en) 2020-12-24
KR20200123155A (ko) 2020-10-28
CN112272675A (zh) 2021-01-26
EP3755718A1 (en) 2020-12-30
IL276548A (en) 2020-09-30
CA3092037A1 (en) 2019-08-29
SG11202007495SA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
JP7605912B2 (ja) Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞
US20220324991A1 (en) Bcma-binding antibodies and uses thereof
US20210038646A1 (en) Chimeric antigen receptors targeting the tumor microenvironment
US20200024358A1 (en) Trispecific antigen binding proteins
TW201936633A (zh) 標靶至cd70的嵌合抗原受體
IL268895B2 (en) Compositions and methods for inhibition of lineage specific proteins
KR20170128234A (ko) Ror1에 특이적인 항체 및 키메라 항원 수용체
CN114149511A (zh) 靶向b细胞成熟抗原的嵌合抗原受体
KR20170057298A (ko) Cd19에 특이적인 항체 및 키메라 항원 수용체
WO2023006118A1 (en) Anti-cd33 antibodies and uses thereof
KR20230015348A (ko) Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물
JP2023519970A (ja) 抗原ターゲティングされた免疫療法における抗原陰性細胞死の増進
JP2025529878A (ja) 新規な抗ｌｉｌｒｂ２抗体及びその使用
WO2023006117A1 (en) Antibodies against cll1 and constructs thereof
US20250333526A1 (en) Antibodies capable of binding to ox40, variants thereof and uses thereof
EP4378953A1 (en) Cd229 targeting moiety for the tratment of cd229 positive cancer
WO2024140641A1 (zh) 靶向ror1的抗原结合蛋白
EA044652B1 (ru) Связывающие bcma антитела и их применение
US20240226298A1 (en) Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
JP2024532167A (ja) 抗ｆｌｔ３抗体、ｃａｒ、ｃａｒ ｔ細胞、及び使用方法
HK40108858A (zh) 抗cll1抗体及其构建体
WO2026001894A1 (zh) 靶向axl的嵌合抗原受体及其用途
HK40108020A (zh) 抗cd33抗体及其用途
HK40039303A (en) Chimeric antigen receptors targeting cd70

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230515

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240402